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Objective: To investigate the efficacy of topical 90%
medical-grade kanuka honey and 10% glycerine
(Honevo) as a treatment for rosacea.
Design: Randomised controlled trial with blinded
assessment of primary outcome variable.
Setting: Outpatient primary healthcare population from
5 New Zealand sites.
Participants: 138 adults aged ≥16, with a diagnosis
of rosacea, and a baseline blinded Investigator Global
Assessment of Rosacea Severity Score (IGA-RSS) of
≥2. 69 participants were randomised to each treatment
arm. 1 participant was excluded from the Honevo
group, and 7 and 15 participants withdrew from the
Honevo and control groups, respectively.
Interventions: Participants were randomly allocated
1:1 to Honevo or control cream (Cetomacrogol), applied
twice daily for 8 weeks.
Main outcome measures: The primary outcome
measure was the proportion of participants who had a
≥2 improvement in the 7-point IGA-RSS at week 8
compared to baseline. Secondary outcomes included
change in IGA-RSS and subject-rated visual analogue
score of change in severity (VAS-CS) on a 100 mm
scale (0 mm ‘much worse’, 100 mm ‘much improved’)
at weeks 2 and 8.
Results: 24/68 (34.3%) in the Honevo group and 12/
69 (17.4%) in the control group had a ≥2 improvement
in IGA-RSS at week 8 compared to baseline (relative risk
2.03; 95% CI 1.11 to 3.72, p=0.020). The change in
IGA-RSS for Honevo compared to control at week 2
minus baseline was −1 (Hodges-Lehman estimate, 95%
CI −1 to 0, p=0.03), and at week 8 minus baseline was
−1 (Hodges-Lehman estimate, 95% CI −1 to 0,
p=0.005). The VAS-CS at week 2 was 9.1 (95% CI 3.5
to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7
to 18.9)¸ p<0.001 for Honevo compared to control.
Conclusions: Honevo is an effective treatment for
rosacea.
Trial registration number: This trial was registered in
the Australian and New Zealand Clinical Trials Registry
ACTRN12614000004662.
INTRODUCTION
Rosacea is a common chronic inﬂammatory
skin condition which primarily affects the
face, and occurs in up to 10% of the adult
population.1–4 There is no cure, and affected
individuals may experience substantial mor-
bidity. There is a range of treatment options,
including several topical and oral antibiotics,
however, these are only partially effective and
side effects may limit their use4–7 Also, there
are global concerns about the increasing
rates of resistance to antibiotics resulting
from their widespread use, particularly with
long-term use in chronic conditions.8 9 For
example, the United Kingdom Standing
Medical Advisory Committee now recom-
mends the fewest number of antibiotic
courses should be prescribed for the shortest
period possible.10
Among the alternative therapies to antibio-
tics, medical-grade kanuka honey is of inter-
est due to its potent antibacterial and
anti-inﬂammatory activities.11–15 The patho-
physiological rationale underlying its use is
that rosacea is an inﬂammatory disorder, and
that antigenic proteins related to the bacter-
ium Bacillus oleronius isolated from the
Demodex folliculorum mite, which infests the
skin in rosacea, exacerbates this inﬂamma-
tory response.16 17 Furthermore, people with
rosacea express abnormally high levels of the
antimicrobial peptide cathelicidin, which
promotes the inﬂammatory response in
rosacea.18
Strengths and limitations of this study
▪ This is a randomised placebo-controlled trial of
8 weeks of treatment for rosacea with either
topical 90% medical-grade kanuka honey and
10% glycerine cream (Honevo) or a non-ionic
paraffin-based cream (cetomacragol).
▪ Owing to the nature of the products being
assessed, participants were not able to be
blinded to the treatment arms.
▪ The primary outcome variable for this study
(Investigator Global Assessment of Rosacea
Severity Score) was assessed by investigators who
were blinded to randomisation throughout the trial.
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A recent pilot study of topical medical-grade kanuka
honey as a treatment for rosacea found it to be an accept-
able and potentially effective treatment.19 The addition
of 10% glycerine to the honey has resulted in a product
that is easier to apply to the skin. In this randomised con-
trolled trial, we have investigated the efﬁcacy of kanuka
honey in the treatment of rosacea. We designed the trial
to overcome the recognised limitations of previous
studies, in particular to ensure that there was blinded
investigator assessment of rosacea severity.6
METHODS
This parallel group, randomised, controlled trial with
assessor blinding was undertaken at a hospital-based
research facility and four community-based research and/
or primary care sites in New Zealand. Ethics approval was
obtained from the Central Health and Disability Ethics
Committee (13/CEN/118). Adults aged 16 or over with a
doctor’s diagnosis of rosacea on the face, and a baseline
blinded Investigator Global Assessment of Rosacea Severity
Score (IGA-RSS) of facial rosacea of ≥2 were recruited.
The IGA-RSS is a 7-point scale (from 0: ‘clear’, to 6:
‘severe’) that provides an integrated assessment of rosacea
severity based on the principal facial signs of papules/pus-
tules, inﬂammatory lesions, erythema and telangiectasia5
(see online supplementary table S1). Participants were
identiﬁed at the time of ﬁrst presentation or, with their
primary care practitioner’s consent, from pre-existing data-
bases, or by public advertisement.
Exclusion criteria included current requirement for
systemic corticosteroids, or systemic corticosteroid treat-
ment in the 4 weeks prior to visit 1, current requirement
for oral or topical antibiotic therapy for rosacea, current
requirement for topical corticosteroid treatment for
rosacea, known or suspected allergy to honey, or
Cetomacrogol control cream, or any other condition
which, at the investigators discretion, it was believed may
present a safety risk or impact the feasibility of the study
or the study results.
Participants attended for 3 visits (see online supplemen-
tary table S2). Visit 1 (week 0) consisted of consent, base-
line assessments (the IGA-RSS), a participant-rated
rosacea severity visual analogue score (VAS-S) on a
100 mm scale (0 mm being ‘mildest possible’ symptoms
and 100 mm being ‘worst possible’ symptoms), and a
participant-rated dermatology quality of life index
(DLQI),20 followed by randomisation to Honevo or
Cetomacrogol cream (control). At visit 2 (week 2) and
visit 3 (week 8), as well as the IGA-RSS and the DLQI, par-
ticipants completed a subjective rosacea ‘change in sever-
ity’ visual analogue scale (VAS-CS) on a 100 mm scale
(0 mm being ‘much worse’ and 100 mm being ‘much
improved’). Participants’ diaries were used throughout the
study to capture each participant’s weekly subjective VAS-S,
their use of randomised treatment throughout the 8-week
study period, and any general comments including
adverse events throughout the study.
Randomisation and blinding
Treatment allocation was randomised using a computer
generated sequence concealed to investigators by enclos-
ing the proposed treatment arm in an opaque envelope
that was opened only by primary investigators after
informed consent was obtained from each participant.
Participants were randomised in a 1:1 ratio to the topical
application of Honevo or control cream. Owing to the
nature of Honevo, it was not possible to blind the parti-
cipants and primary investigators to the treatment alloca-
tion. An independent investigator at each site remained
blinded to the treatment allocation throughout the
study to perform the blinded IGA. The blinded investi-
gator undertook only the IGA-RSS assessment for this
study, and was not involved in any other study proce-
dures. Participants were instructed not to communicate
with the blinded investigator during the assessments.
Randomised treatments
The Investigational Product was topical medical-grade
kanuka honey with 10% glycerine content (Honevo).
The control cream was Cetomacrogol, a liquid parafﬁn
and white soft parafﬁn topical emollient.21 22 The parti-
cipants were instructed to apply an appropriate amount
of cream to the affected area twice daily for 30–60 min
per application, for 8 weeks, and to remove the treat-
ment with warm water as desired. Participants were
asked not to use any additional treatment for their
rosacea for the duration of the study, as per the exclu-
sion criteria.
Outcome measures
The primary outcome measure was the proportion of
participants who had a ≥2 improvement (reduction) in
the IGA-RSS at week 8 (designated ‘responders’). This
measure represents a clinically meaningful improvement
in severity of rosacea. The secondary outcome measures
included the change from baseline in IGA-RSS at weeks
2 and 8; the participant-rated VAS-CS at weeks 2 and 8;
the change from baseline in participant-rated VAS-S at
weeks 2 and 8; the weekly diary-documented Rosacea
severity VAS-S from participant diaries; the change from
baseline in the participant-rated DLQI20 at weeks 2 and
8; withdrawals due to worsening of Rosacea; adverse
events; and the daily self-reported use of Honevo (appli-
cations per day). Data for all participants was included
for analysis up until the time the participant withdrew
from the study or became ineligible due to the use of
prohibited medications.
Sample size and study power
We anticipated the proportion of participants in the
control group who respond with a ≥2 reduction in
blinded IGA would be between 25% and 50%.6 A total
of 124 participants (62 in each group) has 80% power at
5% signiﬁcance to detect a 25% response rate in the
control group, and a 50% response rate in the Honevo
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group. We recruited 138 participants to allow for a 10%
drop-out rate.
Statistical methods
The study was analysed by an intention to treat, with the
participants who withdrew considered to be non-
responders. The prespeciﬁed statistical analysis was logis-
tic regression for the difference in proportions with
response.
Relative risks for a ≥2 point change in IGA-RSS at
week 8 from baseline and for total study withdrawal were
calculated, with p values using Fisher’s exact test. ORs
were also calculated from logistic regression
For the Likert-scaled variables, the Wilcoxon test, and
Hodges-Lehman estimator of location shift for the differ-
ence between treatments were used. DLQI and VAS vari-
ables were analysed by analysis of covariance (ANCOVA)
with the baseline value as a continuous covariate and
the randomisation as the main predictor variable. The
estimates for these analyses are interpreted as the differ-
ence between randomised groups adjusted for baseline.
Applications per day were analysed by analysis of vari-
ance (ANOVA) with the response variable as the mean
average number of applications per day, predictor vari-
able randomisation group, and using the number of
days in the trial as a weight, to account for variations in
the number of days of application.
In a post hoc analysis, the proportion of participants
in whom the IGA-RSS was zero (clear of rosacea) at
week 8 was calculated.
SAS V.9.3 was used.
RESULTS
The ﬂow of participants in the study is shown in
ﬁgure 1. There were 69 participants randomised to
control and 69 to Honevo. One Honevo participant was
subsequently excluded due to the use of a prohibited
medication on enrolment, and their data was not used
in the consequent analysis. The characteristics of the
participants are shown in table 1. Participants were pre-
dominantly aged between 50 and 70 years, and had had
rosacea for a mean of 15 years. Nineteen per cent of par-
ticipants in each group had previously used oral antibio-
tics for rosacea, while 44% and 38% had previously used
any topical treatments for rosacea in the Honevo and
control groups, respectively. There were 7/68 (10.3%)
withdrawals in the Honevo group (3 worsening rosacea,
2 took prohibited medications, 2 for other reasons unre-
lated to the study) and 15/69 (21.7%) withdrawals in
the control group (8 worsening rosacea, 2 took prohib-
ited medications, 1 did not want to take the control
medication, 1 found the study inconvenient, and 3 for
reasons unrelated to the study).
Primary outcome
There were 24/68 (34.3%) in the Honevo group and
12/69 (17.4%) in the control group who had a ≥2
improvement in IGA-RSS at week 8 compared to base-
line (relative risk 2.03 (95% CI 1.11 to 3.72), p=0.020.
The corresponding OR was 2.59 (1.17 to 5.74).
Secondary outcomes
The change from baseline in IGA-RSS for participants
who did not withdraw is shown in table 2, online supple-
ment table S3 and ﬁgure 2. The change in IGA-RSS for
Honevo compared to control at week 2 minus baseline
was −1 (Hodges-Lehman estimate, 95% CI −1 to 0,
p=0.03), and at week 8 minus baseline was −1
(Hodges-Lehman estimate, 95% CI −1 to 0, p=0.005;
table 3). The subject-rated VAS-CS at week 2 was 9.1 (CI
3.5 to 14.7), p=0.002, and at week 8 was 12.3 (CI 5.7 to
18.9), p<0.001 for Honevo compared to control, repre-
senting greater improvement with Honevo. There was no
signiﬁcant difference in diary-captured VAS-S, adjusted
for baseline, at any of the time points between weeks 2
and 8 (see online supplementary table S4).There was no
signiﬁcant difference in the participant-rated DLQI
adjusted for baseline at week 2 (−0.3, CI −1.1 to 0.6,
p=0.51) or week 8 (−0.01, CI −0.7 to 0.7, p=0.97).
The number of applications per day between the ran-
domised treatments was similar (mean (SD) 1.84 (0.23)
vs 1.86 (0.20) for the Honevo and control groups,
respectively, difference: −0.02 (95% CI −0.10 to 0.05),
p=0.55).
In a post hoc analysis, the proportion of participants
in whom the IGA-RSS score at week 8 was zero, (ie, full
resolution of rosacea) was 9/68 (13.2%) and 2/69
(2.9%) in the Honevo and control groups, respectively,
relative risk 4.6 (95%CI 1.0 to 20.4, p=0.031).
In the Honevo group, 23 participants reported 31
adverse events; 17 rosacea related, (3 of which resulted
in withdrawal of the participants), and 14 unrelated to
rosacea (see online supplementary table S5). In the
control group, 27 participants reported 36 adverse
events; 22 rosacea related, (8 of which resulted in with-
drawal of participants), and 14 unrelated to rosacea.
DISCUSSION
This randomised controlled trial has demonstrated that
topical 90% medical-grade kanuka honey and 10% gly-
cerine (Honevo) is an effective and well tolerated treat-
ment for rosacea. About one-third of participants had a
clinically signiﬁcant improvement in the IGA-RSS after
8 weeks of Honevo treatment, twofold greater than that
observed with the control treatment. We recommend
consideration of the use of kanuka honey as a treatment
for rosacea.
There are a number of methodological issues that are
important in the consideration of the study ﬁndings.
There are no standard validated tools for assessing the
severity of rosacea, which is inherently difﬁcult due to its
varied clinical characteristics. The priority with this study
of a honey product was to reduce potential bias by blind-
ing of clinical assessments where possible, as the
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Figure 1 Flow of participants
through trial.
Table 1 Baseline characteristics of participants
Mean (SD) Median (IQR) Minimum–maximum
Age at enrolment
Honevo N=68 57.7 (13.7) 58.2 (46.7–68.3) 23.4–86.5
Control N=69 58.9 (15.9) 60.1 (49.0–68.6) 18.2–90.1
All N=137 58.3 (14.8) 58.9 (48.1–68.6) 18.2–90.1
Age at diagnosis
Honevo N=64 42.2 (15.4) 40 (30–51.5) 19–80
Control N=67 43.6 (15.4) 43 (35–55) 10–79





Female 32 (47.1) 36 (52.2)
History of oral antibiotics 13 (19.1) 13 (18.8)
History of topical therapy 24 (35.3) 20 (29.0)
History of topical steroid 6 (8.8) 6 (8.7)
European 64 (94.1) 68 (98.6)
Maori 4 (5.9) 0 (0)
Asian 0 (0) 1 (1.5)
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participant could not be blinded due to the appearance
and smell of Honevo. It was for this reason we chose to
use the seven-point IGA-RSS representing a global assess-
ment of severity of rosacea that was undertaken by an
investigator who was blinded to treatment.
The primary outcome variable identiﬁed the propor-
tion in each treatment arm who had a two-point reduc-
tion or more in IGA-RSS, representing a clinically
meaningful improvement in severity of rosacea, for
example, a change from ‘severe’ to ‘moderate’, or from
‘moderate’ to ‘mild’. Thirty-four per cent of those who
were randomised to Honevo had an IGA-RSS improve-
ment of two or more at 8 weeks compared to 17% of the
placebo group, and 13% achieved full resolution of
rosacea compared to 3% in the placebo group.
Although these point estimates are consistent with effect-
iveness, the CIs are wide which could be consistent with
a small effect or quite large effect. This is especially the
case for the post hoc analysis of IGA-RSS for the
proportion of participants with complete resolution,
which although it favours the active treatment, could be
consistent with quite a small effect. The estimate of the
location shift for the difference between the treatments
was −1, (95% CI −1 to 0) at both weeks 2 and 8 and the
estimated change in IGA-RSS at week 8 adjusted for
baseline was −0.6 (95% CI −1.1 to −0.2). These ﬁndings
reﬂect the variability in response to Honevo, perhaps
dependent on subtypes of rosacea which were not
assessed in this study.
In addition, we assessed patient-reported outcomes,
based on participant’s assessment of current severity of
symptoms (VAS-S), participant’s perceived change in
severity (VAS-CS), and the DLQI questionnaire, to
provide a comprehensive assessment of efﬁcacy. The
VAS-CS at the 2-week and 8-week clinic visits was signiﬁ-
cantly better with Honevo. However, there was no differ-
ence with the 2-week and 8-week DLQI assessments or
the weekly diary VAS-S measures. Thus, the patient
assessments were not completely consistent with the
other assessments of efﬁcacy. This could mean that the
variability in these led to insufﬁcient statistical power to
detect a difference, or in the context of rosacea, that an
ideal measurement related to efﬁcacy that is sensitive to
change needs further development. The rosacea
quality-of-life instrument has been recently reviewed in
addition to the DLQI and a generic health-related
quality-of-life instrument, the SF-36, in rosacea, and may
be a suitable instrument for future research.21 In the
absence of a validated VAS for rosacea severity, it is difﬁ-
cult to comment on the clinical relevance of a reduction
of 11 points from baseline in the VAS-S or the 12.3
improvement in VAS-CS in the Honevo group compared
to the control group after 8 weeks. As these outcomes
were participant assessed and participants could not be
blinded to the interventions, there is a risk of detection
Table 2 Contingency table of blinded Investigator Global
Assessment of Rosacea Severity Score (IGA-RSS) week 8
change from baseline by randomisation in the participants
who completed the study
Change from
baseline Honevo N/61 (%) Control N/54 (%)
−3 11 (18.0) 1 (1.9)
−2 13 (21.3) 11 (20.4)
−1 20 (32.8) 17 (31.5)
0 14 (23.0) 15 (27.8)
1 3 (4.9) 8 (14.8)
2 0 (0) 2 (3.7)
IGA-RSS: blinded Investigator Global Assessment of Rosacea
Severity Score based on a seven-point scale (0 ‘clear’ to 6
‘severe’.
Figure 2 The difference from
baseline in IGA-RSS at week 8
for control and Honevo.
Horizontal lines are the 25%,
median and 75% quartiles, the
symbol is the mean and the
whiskers go from maximum to
minimum.
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bias in this methodology. The DLQI is a questionnaire
non-speciﬁc to rosacea and may not have been sensitive
enough to capture changes associated with this condi-
tion alone. The drop-out rate for this study was greater
than anticipated, which will need to be factored into
future research in similar clinical studies. The greater
number of withdrawals due to worsening rosacea in the
control group (12% vs 4%), and overall withdrawals is
likely to have led to an underestimation of the efﬁcacy
of Honevo, as these participants did not undergo assess-
ment of the secondary outcome variables following
withdrawal.
Cetomacrogol cream was chosen as a comparator as it
is a non-ionic moisturising cream, often used as a
vehicle for delivery of topical medications.22 23 The treat-
ment was administered for 8 weeks to allow both the
speed of onset and the duration of effect to be assessed.
This identiﬁed that honey had efﬁcacy within 2 weeks of
treatment, with further efﬁcacy obtained during the
8-week treatment period. Adverse event data did not
allow us to reliably ascertain whether the rosacea-speciﬁc
adverse events such as burning, itching, peeling, sting-
ing, dry skin and pain were associated only with the
application of the investigational medicine or whether
they were ongoing rosacea symptoms. However, it was
reassuring that the number of participants with
rosacea-speciﬁc adverse events was similar between
Honevo and the parafﬁn-based emollient control cream.
Notwithstanding the limitations of comparing differ-
ent primary outcome variables utilised in other studies
of rosacea, it is interesting to note the ﬁndings from
placebo-controlled studies of topical metronidazole or
azelaic acid, two of the more commonly used treatments
for rosacea.4–7 In studies of topical metronidazole, the
relative risk of improvement with the physician’s global
evaluation of improvement was 1.95 (95% CI 1.5 to 2.6),
and in studies of azelaic cream the relative risk of
participant-assessed improvement was 1.52 (95% CI 1.3
to 1.8).6 24 In our study, the relative risk of IGA-RSS
improvement with Honevo was 2.0 (95%CI 1.1 to 3.7),
and in the post hoc analysis the relative risk of resolution
was 4.6 (95% CI 1.0 to 20.4). It is difﬁcult to indirectly
compare the results of these studies of two other active
treatments against placebo with the study reported here,
as the characteristics of the research participants may
have been quite different and the outcome variable of
global improvement may not correspond to that used in
this study. Despite this, we have found sufﬁcient evi-
dence of efﬁcacy, albeit with wide CIs, that a reasonable
next stage is to conduct randomised controlled trials
comparing Honevo with topical metronidazole or
azelaic cream.
The mechanism of action was not assessed in this
study, however, there are a number of potential mechan-
isms relevant to the efﬁcacy demonstrated with kanuka
honey in this study. First, kanuka honey has a number of
different anti-inﬂammatory effects, including inhibition
of neutrophil superoxide production,13 reduction in
inﬂammatory leucocyte inﬁltration and arachidonic-
induced oedema,13 and stimulation of macrophage
release of tumour necrosis factor α,15 a cytokine with a
crucial role in wound healing.25 26 These properties may
be relevant as rosacea is a chronic inﬂammatory dis-
order, characterised by inﬂammatory cell inﬁltration,
vascular dilation and tissue oedema.1 3 6 In addition,
kanuka honey has high antibacterial activities against a
Table 3 Clinic-based secondary outcome variables (all Honevo minus control)
Comparison
N with data
Hodges-Lehman estimate (95% CI) p ValueHonevo Control
IGA-RSS week 2 66 66 0 (−1 to 0) 0.26
IGA-RSS week 8 61 54 0 (−1 to 0) 0.06
IGA-RSS week 2 minus baseline 66 66 −1 (−1 to 0) 0.03
IGA-RSS week 8 minus baseline 61 54 −1 (−1 to 0) 0.005
Estimate (95% CI) p Value
IGA-RSS week 8 adjusted for baseline* 61 54 −0.6 (−1.1 to −0.2) 0.003
Mean difference (95% CI) p Value
VAS-CS week 2 66 66 9.1 (3.5 to 14.7) 0.002
VAS-CS week 8 61 54 12.3 (5.7 to 18.9) <0.001
VAS-S week 2 66 66 −3.6 (−9.9 to 2.7) 0.26
VAS-S week 2 minus baseline 66 66 −2.9 (−9.2 to 3.5) 0.38
VAS-S week 8 61 54 −4.5 (−11.6 to 2.6) 0.21
VAS-S week 8 minus baseline 61 54 −11.0 (−18.0 to −3.9) 0.003
IGA-RSS: blinded Investigator Global Assessment of Rosacea Severity Score, based on a seven-point scale (0 ‘clear’ to 6 ‘severe’).
VAS-CS: Participant-rated assessment of change in severity of rosacea based on a 100 mm VAS scale (0 mm ‘much worse’ to 100 mm ‘much
improved’).
VAS-S: Participant-rated assessment of severity of rosacea based on a 100 mm VAS scale (0 mm ‘mildest possible’ symptoms and 100 mm
‘worst possible’ symptoms).
Analysis of variance (ANOVA) with baseline reading as a covariate, normality assumptions not well met.
*ANOVA with baseline reading as a co-variate, normality assumptions not well met.
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wide range of bacteria, including Bacillus subtilis,
Propionibacterium acne and Staphylococcus aureus,11 12 14
properties which may be beneﬁcial in view of the pro-
posed role of B. oleronius in the inﬂammatory response
in rosacea. The effect of honey on B. oleronius and the
Demodex folliculum mite requires further investigation.
In conclusion, this randomised controlled trial has
demonstrated the clinical efﬁcacy and tolerability of
90% medical-grade kanuka honey and 10% glycerine
(Honevo) in the treatment of rosacea. Honevo can be
recommended for the treatment of rosacea; however,
further randomised controlled trials comparing Honevo
with topical metronidazole and azelaic acid are now
required to determine its relative efﬁcacy and side effect
proﬁle compared to these agents.
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